4.8 Article

Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury

Journal

BMC MEDICINE
Volume 17, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12916-019-1268-y

Keywords

Cathelicidin; CRAMP; LL-37; Ischemia; reperfusion injury; Cardiomyocyte; Apoptosis

Funding

  1. National Natural Science Foundation of China [81722008, 81600228, 91639101, 81570362, 81770401, 91642114, 81573420]
  2. National Key Research and Development Program of China [2017YFC1700401]
  3. Innovation Program of Shanghai Municipal Education Commission [2017-01-07-00-09-E00042]
  4. Science and Technology Commission of Shanghai Municipality [18410722200, 17010500100]
  5. development fund for Shanghai talents [T.39-0112-17-201]
  6. Shanghai Municipal Health Commission [20154Y0026]
  7. Jiangsu Province Recruitment Plan for High-level, Innovative and Entrepreneurial Talents
  8. Fundamental Research Funds for the Central Universities [JUSRP51613A, JUSRP11866]
  9. Wuxi Science & Technology Development Funds for International Science & Technology RD Cooperation [WX0303B010518180007PB]
  10. National First-class Discipline Program of Food Science and Technology [JUFSTR20180103]
  11. National Institutes of Health (NCATS grant) [UH3 TR000901]

Ask authors/readers for more resources

BackgroundCathelicidins are a major group of natural antimicrobial peptides which play essential roles in regulating host defense and immunity. In addition to the antimicrobial and immunomodulatory activities, recent studies have reported the involvement of cathelicidins in cardiovascular diseases by regulating inflammatory response and microvascular dysfunction. However, the role of cathelicidins in myocardial apoptosis upon cardiac ischemia/reperfusion (I/R) injury remains largely unknown.MethodsCRAMP (cathelicidin-related antimicrobial peptide) levels were measured in the heart and serum from I/R mice and in neonatal mouse cardiomyocytes treated with oxygen glucose deprivation/reperfusion (OGDR). Human serum cathelicidin antimicrobial peptide (LL-37) levels were measured in myocardial infarction (MI) patients. The role of CRAMP in myocardial apoptosis upon I/R injury was investigated in mice injected with the CRAMP peptide and in CRAMP knockout (KO) mice, as well as in OGDR-treated cardiomyocytes.ResultsWe observed reduced CRAMP level in both heart and serum samples from I/R mice and in OGDR-treated cardiomyocytes, as well as reduced LL-37 level in MI patients. Knockdown of CRAMP enhanced cardiomyocyte apoptosis, and CRAMP KO mice displayed increased infarct size and myocardial apoptosis. In contrast, the CRAMP peptide reduced cardiomyocyte apoptosis and I/R injury. The CRAMP peptide inhibited cardiomyocyte apoptosis by activation of Akt and ERK1/2 and phosphorylation and nuclear export of FoxO3a. c-Jun was identified as a negative regulator of the CRAMP gene. Moreover, lower level of serum LL-37/neutrophil ratio was associated with readmission and/or death in MI patients during 1-year follow-up.ConclusionsCRAMP protects against cardiomyocyte apoptosis and cardiac I/R injury via activation of Akt and ERK and phosphorylation and nuclear export of FoxO3a. Increasing LL-37 might be a novel therapy for cardiac ischemic injury.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available